iPS Cell Stock Project HLA-genome-edited iPS cells

MENU

HLA-genome-edited iPS cells

What are HLA-genome-edited iPS cells?

HLA-genome-edited iPS cells are designed to reduce the risk of immune rejection. The CiRA Foundation plans to manufacture and provide these cells by targeting HLA-A, -B, and -CIITA for the genome-edited knockout.

Advantages

It has been estimated that only seven HLA-genome-edited iPS cell lines could cover 95% of the Japanese population, and 12 cell lines could cover the entire world. An even smaller number of cell lines could serve most of the world's population. In addition, compared to cells which have had their HLA completely knocked out to reduce the risk of immune rejection, our cells are capable of suppressing both T and NK cell activity, because they retain HLA-C and HLA-E.

The iPS cell line that using CRISPR-Cas9 genome editing to knocked out the CIITA gene that expresses HLA-A, HLA-B and HLA-Class II.

Future challenges

While the risk of immune rejection is reduced by HLA gene editing, it is not completely eliminated. Gene-edited technologies for clinical application have never been tested in Japan. Therefore, the safely and the quality of the cells must be examined carefully.

Glossary

HLA, or human leukocyte antigens, describes cell-surface proteins that allow the body to distinguish self cells from non-self cells. HLA are found on various cell types other than leukocytes. There are tens of thousands of combinations of HLA types. HLA are classified into three types, but HLA-A, -B, and -C, which are all class 1, play a primary role in the immune response to transplanted cells.

HLA-genome-edited iPS cells list


Clinical-grade cells

HLA-genome-edited iPS cells For profit Non-profit institution
Clinical-grade cells 200,000 yen/vial free

✓It is provided free of charge to non-profit organizations.

✓Approval from the iPS Cell Stock Committee is required before cells can be provided.

✓Even when you apply for research purpose (non-clinical), a clinical-grade cell line is provided.Under the research condition, do not use in humans.

✓International Shipping: Receiving Organization, whether profit or non-profit, is required to arrange for a shipping and transportation from CiRA Foundation to its research location by its cost. CiRA Foundation will not responsible for any of loss and damages of iPSC stock during the shipment or the transportation.

Donor ID Gene Knockout Clone ID
QHJI QHJI14s04-AB II-KO-03
QHJI QHJI14s04-AB II-KO-11
QHJI QHJI14s04-AB II-KO-12

Since the clinical-grade cells with genome editing can also be used for research purpose, we generally recommend this clinical one for regenerative medicine.
It is also possible to provide the following research-grade cells with genome editing. However, please note that this research-grade cells are not same batch as the above clinical-grade cells, and the two lines are completely different in the manufacturing processes including the genome editing manipulation.

Research-grade cells

HLA-genome-edited iPS cells For profit Non-profit institution
Research-grade cells 100,000 yen/vial free

✓It is provided free of charge to non-profit organizations.

✓Approval from the iPS Cell Stock Committee is required before cells can be provided.

✓International Shipping: Receiving Organization, whether profit or non-profit, is required to arrange for a shipping and transportation from CiRA Foundation to its research location by its cost. CiRA Foundation will not responsible for any of loss and damages of iPSC stock during the shipment or the transportation.

Donor ID Gene Knockout Clone ID
DRXT × Ff-XT28s
05-cont
Ff-XT28s05-ABo_To
QHJI Ff-I01s04-AB II-KO-16
Ff-I01s04-AB II-KO-50
Ff-I01s04-AB II-KO-54
Ff-I14s04-AB II-KO-7
Ff-I14s04-AB II-KO-13
Ff-I14s04-AB II-KO-24

MENU

Related Information

For Researchers and Companies
Research Materials(Bioresources)
iPS Cell Stock Project
How to Use the Stock